Analyst consensus rating
Intellia Therapeutics Analyst Rating: Buy
NTLA is rated Buy by 17 analysts with a $23.94 target. As of 2026-08-29.
Direct answer
Intellia Therapeutics's consensus rating is Buy.
17 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.94.
Forecast evidence checked August 29, 2026.
Get free Intellia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.87
- Average price target
- $23.94
- High price target
- $61.00
- Low price target
- $8.00
- Low target gap
- -37.8%
- Target upside
- +86%
- High target gap
- +374%
- Target range width
- 411.8%
- Consensus rating
- Buy
- Analysts
- 17
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Intellia Therapeutics?
Intellia Therapeutics has a verified Buy consensus. The same dataset has an average price target of $23.94.
How far are Intellia Therapeutics's low and high targets from the recorded price?
The low target implies -37.8%, while the high target implies +374%.
How many analysts are included in Intellia Therapeutics's consensus?
The verified consensus includes 17 analysts.
How is Intellia Therapeutics's target upside or downside calculated?
The average target of $23.94 is divided by the recorded price of $12.87, then one is subtracted to produce +86%. This does not guarantee a future return.
When was Intellia Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.